SCHEMBL6840084

SCHEMBL6840084

CS(=O)(=O)c1nccc(-c2csc(N)n2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4B O94953 3/20 0.46
KDM5C P41229 3/20 0.46
KDM5B Q9UGL1 3/20 0.46
KDM4A O75164 2/20 0.46
KDM6B O15054 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
ALDH1A1 P00352 7/20 0.40
MAPT P10636 5/20 0.40
NPC1 O15118 5/20 0.40
HSD17B10 Q99714 3/20 0.40
GFER P55789 1/20 0.40
FBP1 P09467 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LTA4H P09960 4/20 0.38
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24774090 0.78 DYRK1A (0.35) ALDH1A1MAPTNPC1HSD17B10MEN1
SCHEMBL24774281 0.78 PTGS2 (0.39) ALDH1A1MAPTNPC1HSD17B10MEN1
SCHEMBL21067987 0.74 HSP90AA1 (0.55) KDM4BKDM5CKDM5BKDM4AKDM6B
SCHEMBL24774282 0.74 KDM4E (0.40) ALDH1A1MAPTNPC1HSD17B10MEN1
SCHEMBL28146826 0.73 NPC1 (0.45) ALDH1A1NPC1HSD17B10MEN1KMT2A
SCHEMBL24774092 0.73 BPTF (0.37) ALDH1A1MAPTNPC1HSD17B10MEN1
SCHEMBL26643840 0.73 CYP19A1 (0.35) ALDH1A1NPC1HSD17B10KMT2ARAB9A
SCHEMBL28996166 0.73 HSP90AA1 (0.47) ALDH1A1CYP3A4KDM4ECYP2C9LMNA
SCHEMBL30252976 0.73 HSP90AA1 (0.47) ALDH1A1CYP3A4KDM4ECYP2C9LMNA
SCHEMBL5361055 0.72 KDM4E (0.52) KDM5CKDM4AKDM6BKDM2AKDM3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040181066-A1 Tyrosine kinase inhibitors FRALEY MARK E (US) 2004-09-16 US disclosed
WO-2003011838-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181066-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KDM4B 3350/4885KDM5C 2852/4885KDM5B 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.